Olema Oncology to Present at Morgan Stanley 19th Annual Global Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on targeted therapies for women's cancers, announced that Sean P. Bohen, M.D., Ph.D., CEO, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 13, 2021, at 4:15 p.m. ET. A live webcast will be available on Olema's website and archived for 14 days.
Olema’s lead candidate, OP-1250, is currently under evaluation for its effectiveness in treating ER-positive, HER2-negative breast cancer in a Phase 1/2 clinical trial.
Details
News Market Reaction – OLMA
The recorded move for OLMA in the trading session of this news was -0.47%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Monday, September 13, 2021, at 4:15 p.m. ET (1:15 p.m. PT).
A live webcast of the presentation may be accessed under the Investors & Media section of Olema’s website (www.olema.com) and will be archived for 14 days.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally-available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is headquartered in San Francisco.
Contact:
Eva Stroynowski
Vice President, Communications and Investor Relations
eva@olema.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.